Scientists are on track to find a treatment for autoimmune hair loss
A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...
News-Medical.Net on MSN2d
Researchers develop new compound to treat alopecia areata
A research group, led by Dr. Pavel Majer from IOCB Prague, in collaboration with the laboratories of Barbara Slusher and ...
EurekAlert!3d
Scientists from IOCB Prague are on track of finding a treatment for autoimmune hair loss
Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia areata, which causes hair ...
Medscape4d
New Bifunctional Drug Shows Sustained Effect in Alopecia Areata
In an alopecia areata trial, a novel bifunctional therapy that blocks signaling of the interleukin-7 and TSLP pathways ...
Technology Networks2d
Autoimmune Hair Loss Could Be Treated With Derivatives of Itaconates
Researchers have developed a compound that could potentially treat the autoimmune disorder alopecia, which causes hair loss ...
MPR1d
Ivarmacitinib 4mg, 8mg Efficacious for Adults With Severe Alopecia Areata
HealthDay News — For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses of 4 and 8mg is efficacious and tolerable, according to a study ...
Medical Dialogues2d
Prediabetes and Associated Risk in Young Adults - Alopecia Areata and Erectile Dysfunction
The rising prevalence of prediabetes among young adults signals early metabolic dysfunction, significantly increasing the ...
The American Journal of Managed Care1d
Pediatric Alopecia Areata Treatment With Baricitinib, Combination Therapies, Patient Adherence
In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...
HealthDay on MSN2d
AAD: Ivarmacitinib 4 mg, 8 mg Efficacious for Adults With Severe Alopecia Areata
For adults with severe alopecia areata (AA), ivarmacitinib, a selective Janus kinase 1 (JAK1) inhibitor, at doses o ...
Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to ...